2,5-Bis(trifluoromethyl)benzoyl chloride → (2Z)-1-[2,5-bis(trifluoromethyl)phenyl]-2-(3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene)ethanone
Reaction equation
[I-].[CH2:2]([N+:6]1[C:10]([CH3:11])=[C:9]([CH3:12])[S:8][C:7]=1[CH3:13])[CH2:3][CH2:4][CH3:5].[F:14][C:15]([F:30])([F:29])[C:16]1[CH:24]=[CH:23][C:22]([C:25]([F:28])([F:27])[F:26])=[CH:21][C:17]=1[C:18](Cl)=[O:19]>CN(C1C=CN=CC=1)C>[F:14][C:15]([F:29])([F:30])[C:16]1[CH:24]=[CH:23][C:22]([C:25]([F:26])([F:27])[F:28])=[CH:21][C:17]=1[C:18](=[O:19])/[CH:13]=[C:7]1\[S:8][C:9]([CH3:12])=[C:10]([CH3:11])[N:6]\1[CH2:2][CH2:3][CH2:4][CH3:5]Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
In a 20 mL vial 3-butyl-2,4,5-trimethylthiazol-3-ium iodide (48 mg in 0.5 mL DMA, 0.16 mmol, 1 equiv.) was added, followed by TEA (38 mg in 0.5 mL DMA, 0.37 mmol, 2.4 equiv.) and the solution went black. DMAP (2 mg in 0.5 mL DMA, 0.016 mmol, 0.1 equiv) was added next, followed by 2,5-bis(trifluoromethyl)benzoyl chloride (0.9 mL of 0.2M in DMA, 1.2 equiv). The mixture was shaken overnight at room temperature and then concentrated in vacuo. The resulting residue was taken up in 1:1 DMSO/MeOH and purified by reverse phase HPLC using a method analogous to that described in Example 53 to provide the title compound. 1H NMR (500 MHz, DMSO-d6/D2O) δ ppm 0.89 (t, 3 H) 1.28-1.38 (m, 2 H) 1.56-1.64 (m, 2 H) 2.19 (s, 3 H) 2.23 (s, 3 H) 3.92-3.98 (m, 2 H) 6.02 (s, 1 H) 7.82-7.84 (m, 1 H) 7.93-7.97 (m, 1 H) 7.98-8.02 (m, 1 H); MS (ESI) m/z 424 (M+H)+.
Workup
- concentrationconcentrated in vacuo
- custompurified by reverse phase HPLC
Sources & evidence
- ORD record
- ord-2efd5c27cd0d46d09c9680e70614e2b4
- Source dataset
- uspto-grants-2013_07
- Patent number
- US08481574B2
Reaction notes
Loading…